Taro Pharmaceutical Industries Ltd. (the "Company" or "Taro," Pink Sheets: TAROF) reported that its U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc. ("Taro USA") has received approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Flo-PredTM (prednisolone acetate oral suspension) equivalent to 5 mg/5 mL and 15 mg/5 mL prednisolone in Taro's patent-protected NonSpilTM liquid drug delivery system.
(more...)